- Healthy male subjects between the ages of 18 and 50 years inclusive. Healthy is
defined as no clinically relevant abnormalities identified by a detailed medical
history, full physical examination, including blood pressure and pulse rate
measurement, 12-lead ECG and clinical laboratory tests.
- Evidence of a personally signed and dated informed consent document indicating that
the subject (or a legally acceptable representative) has been informed of all
pertinent aspects of the trial.
- Skintype I-III with a distance from base of scaphoid to antecubital fossa >26cm on
their forearms.
- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, genitourinary, psychiatric, neurologic,
or allergic disease (including drug allergies, but excluding untreated, symptomatic,
seasonal allergies at time of dosing).
- Use of biologics including any live vaccines within 3 months prior to screening or
prior treatment with an antibody in a previous clinical trial or treatment with an
immunoglobulin in the past 6 months.
- 12-lead ECG demonstrating QTcF >450 msec at screening.
- Subjects with scars or tattoos on the forearms, or with evidence of sunburn, or
excessive hairy volar forearms.